Interaction of hepatic stellate cells with diverse types of immune cells: Foe or friend?
Interaction of hepatic stellate cells with diverse types of immune cells: Foe or friend?
复制标题
DOI：
10.1111/jgh.12017
复制
发表时间：
2013-08-01
影响因子：
4.1
通讯作者：
Jeong, Won-Il
中科院分区：
文献类型：
--
作者：
Yi, Hyon-Seung;Jeong, Won-Il
活化的肝星状细胞（HSC）被认为是肝纤维化的主要细胞类型，其产生大量的细胞外基质，特别是胶原纤维，以及促纤维化介质，如转化生长因子-β、白细胞介素-6和单核细胞趋化蛋白-1。近年来，越来越多的证据表明，肝脏是一个免疫器官，因为肝脏中富含多种类型的免疫细胞，它们与肝星状细胞的相互作用与肝纤维化的进展密切相关。然而，HSC和免疫细胞之间相互作用的潜在机制在很大程度上仍然未知。最近，多项研究表明，自然杀伤细胞、M2巨噬细胞、调节性T细胞和骨髓来源的CD 11b（+）Gr 1（+）未成熟细胞可改善肝纤维化，而中性粒细胞、M1巨噬细胞、CD 8 T细胞、自然杀伤T细胞和白细胞介素-17产生细胞可加速肝纤维化。然而，关于它们在肝纤维化发生中的作用仍存在争议。在这篇综述中，我们总结了免疫细胞的多样性作用（例如，G.促纤维化/抗纤维化或两者）在肝纤维化形成过程中调节HSC的活化，其中HSC产生的几种介质在与它们的相互作用中起重要作用。此外，目前基于细胞的治疗使用免疫细胞对肝纤维化进行了讨论。
Activated hepatic stellate cells (HSCs) have been considered as a major type of cells in liver fibrosis by producing a huge amount of extracellular matrix, especially collagen fibers, and profibrotic mediators such as transforming growth factor-beta, interleukin-6 and monocyte chemoattractant protein-1. Recently, accumulated evidence suggests that the liver is an immunologic organ because of enrichment of diverse types of immune cells and that their interactions with HSCs are closely related with the progression of liver fibrosis. However, the underlying mechanisms of interaction between HSCs and immune cells remain largely unknown. Recently, several studies have demonstrated that natural killer cells, M2 macrophages, regulatory T cells, and bone marrow derived CD11b(+)Gr1(+) immature cells ameliorate liver fibrosis, whereas neutrophils, M1 macrophages, CD8 T cells, natural killer T cells and interleukin-17-producing cells accelerate liver fibrosis. However, there are still controversial issues about their functions during liver fibrogenesis. In this review, we summarize the diversity roles of immune cells (e. g. profibrotic/antifibrotic or both) in regulating the activation of HSCs during hepatic fibrogenesis, in which several producible mediators by HSCs play important roles in the interaction with them. Moreover, the current cell-based therapies using immune cells against liver fibrosis are discussed.